Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01992536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01992536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)
Lead sponsor
Novartis Vaccines
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
April 30, 2015
Enrollment
194 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease